Sugi Predict

Sugi Predict / Compounds / SCHEMBL7179331

SCHEMBL7179331

SCHEMBL7179331

O=C1CCc2c1cccc2-c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP10 Q53GL7 1/20 0.58
▸ PARP11 Q9NR21 1/20 0.58
▸ ANPEP P15144 2/20 0.45
▸ IL1RN P18510 1/20 0.45
▸ ERAP2 Q6P179 1/20 0.45
▸ ERAP1 Q9NZ08 1/20 0.45
▸ PRCP P42785 1/20 0.44
▸ HDAC4 P56524 1/20 0.41
▸ HDAC2 Q92769 1/20 0.41
▸ HDAC8 Q9BY41 1/20 0.41
▸ HDAC6 Q9UBN7 1/20 0.41
▸ CYP2A6 P11509 1/20 0.41
▸ MAOA P21397 1/20 0.41
▸ MAOB P27338 1/20 0.41
▸ HTR1A P08908 2/20 0.39
▸ HTR7 P34969 2/20 0.39
▸ PLK4 O00444 1/20 0.39
▸ MAPK9 P45984 1/20 0.39
▸ LIMK1 P53667 1/20 0.39
▸ CLK4 Q9HAZ1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16406400 0.92 PARP10 (0.50) PARP10PARP11ANPEPIL1RNERAP2
SCHEMBL23273185 0.88 PARP10 (0.54) PARP10PARP11ANPEPIL1RNERAP2
SCHEMBL7587251 0.88 PARP10 (0.54) PARP10PARP11ANPEPIL1RNERAP2
SCHEMBL28004729 0.86 PARP10 (0.49) PARP10PARP11ANPEPIL1RNERAP2
SCHEMBL15544729 0.82 PARP10 (0.45) PARP10PARP11ALDH1A1GAANPC1
SCHEMBL15543967 0.82 HTR7 (0.43) PARP10PARP11HTR1AHTR7ALDH1A1
SCHEMBL22797299 0.82 PARP10 (0.56) PARP10PARP11ANPEPIL1RNERAP2
SCHEMBL16193421 0.80 PGR (0.44) PARP10PARP11MAOBLIMK1CLK4
SCHEMBL16193477 0.80 HTR1A (0.46) PARP10PARP11MAOBHTR1AHTR7
SCHEMBL13923765 0.79 PARP10 (0.61) PARP10PARP11ALDH1A1GAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3474845-B1 IMMUNOMODULATOR COMPOUNDS CHEMOCENTRYX INC (US) 2024-03-20 — — EP disclosed
US-11793771-B2 Immunomodulator compounds CHEMOCENTRYX, INC. (US) 2023-10-24 — — US disclosed
US-11793771-B2 Immunomodulator compounds CHEMOCENTRYX, INC. (US) 2023-10-24 — — US disclosed
US-11793771-B2 Immunomodulator compounds CHEMOCENTRYX, INC. (US) 2023-10-24 — — US disclosed
US-20230117425-A1 IMMUNOMODULATOR COMPOUNDS CHEMOCENTRYX, INC. 2023-04-20 — — US disclosed
US-11426364-B2 Immunomodulator compounds CHEMOCENTRYX, INC. (US) 2022-08-30 — — US disclosed
CN-109803651-B Immunomodulatory compounds 凯莫森特里克斯股份有限公司 2022-05-31 — — CN disclosed
CN-109665968-B Fused ring compound, preparation method and application thereof 四川科伦博泰生物医药股份有限公司 2022-02-22 — — CN disclosed
US-20210052514-A1 IMMUNOMODULATOR COMPOUNDS CHEMOCENTRYX, INC. 2021-02-25 — — US disclosed
US-20210052514-A1 IMMUNOMODULATOR COMPOUNDS CHEMOCENTRYX, INC. 2021-02-25 — — US disclosed
EP-0576970-B1 Metallocenes with arylsubstituted indenyl-derivatives as ligands, process for their preparation and their use as catalysts HOECHST AG (DE) 1998-01-14 — — EP disclosed
US-5677306-A ANTAGONIZING ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID RECEPTOR, USEFUL FOR TREATING ALL ISCHEMIAS RHONE-POULENC RORER S.A. (FR) 1997-10-14 — — US disclosed
EP-0790076-A2 Catalysts containing metallocenes with arylsubstituted indenyl derivatives as ligands, process and intermediates for the preparation of these metallocenes and their use HOECHST AKTIENGESELLSCHAFT (DE) 1997-08-20 — — EP disclosed
EP-0662971-A1 DERIVATIVES OF 5H,10H-IMIDAZO 1,2-a]INDENO 1,2-e]PYRAZINE-4-ONE, PREPARATION THEREOF AND MEDICAMENTS CONTAINING THEM Aventis Pharma S.A. (FR) 1995-07-19 — — EP disclosed
WO-1994007893-A1 DERIVATIVES OF 5H,10H-IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZINE-4-ONE, PREPARATION THEREOF AND MEDICAMENTS CONTAINING THEM RHONE-POULENC RORER S.A. (FR) 1994-04-14 — — WO disclosed
EP-0576970-A1 Metallocenes with arylsubstituted indenyl-derivatives as ligands, process for their preparation and their use as catalysts HOECHST AKTIENGESELLSCHAFT (DE) 1994-01-05 — — EP disclosed
US-4429149-A PYRETHRUM-RELATED INSECTICIDES FMC CORPORATION (US) 1984-01-31 — — US disclosed
US-4346251-A 4-Substituted-2-indanols FMC CORPORATION (US) 1982-08-24 — — US disclosed
US-4335252-A A4-PHENYL-Z-INDANYL CYCLOPROPANE CARBOXYLATE FMC CORPORATION (US) 1982-06-15 — — US disclosed
US-4263319-A CYCLOPROPYL ESTERS FMC CORPORATION (US) 1981-04-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230117425-A1 IMMUNOMODULATOR COMPOUNDS IL2, IL2RA, C3AR1 PARP10 3000/4885PARP11 2787/4885ANPEP 3272/4885
US-11793771-B2 Immunomodulator compounds IL2, IL2RA, C3AR1 PARP10 3000/4885PARP11 2787/4885ANPEP 3272/4885
US-20210052514-A1 IMMUNOMODULATOR COMPOUNDS IL2, IL2RA, C3AR1 PARP10 2986/4885PARP11 2654/4885ANPEP 3548/4885
US-11426364-B2 Immunomodulator compounds IL2, IL2RA, C3AR1 PARP10 2986/4885PARP11 2654/4885ANPEP 3548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.